The company has not filed an annual or quarterly report since its Q2 FY2018 10-Q, filed Aug 9, 2018. Its latest SEC filing is a CT ORDER from Sep 27, 2018.
10-Q for Q2 FY2018, filed Aug 9, 2018
The sections below describe the company as of the FY2017 annual report.
Sells cancer gene-testing and interpretation services to physicians and biopharmaceutical companies, helping guide treatment choices and cancer drug development.
10-K for FY2017, filed Mar 7, 2018We are a molecular information company focused on fundamentally changing the way in which patients with cancer are evaluated and treated.…View ↗
We offer a full suite of validated clinical assays based on our CGP approach:View ↗
A robust clinical business providing molecular information to physicians;View ↗
Clinical test charges are tied to delivery of results; commercial insurers, Medicare, some hospitals and cancer centers, other institutions, and patients pay for these services. Biopharmaceutical customers pay per test or for testing, data access, and research services over a set period, with research payments sometimes tied to work performed or development and sales milestones.
10-K for FY2017, filed Mar 7, 2018The Company derives revenue from the provision of molecular information services provided to its ordering physicians and biopharmaceutical…View ↗
The Company recognizes revenue from the sale of its molecular information services to clinical customers, including certain hospitals…View ↗
Revenue from sales of the Company’s services to biopharmaceutical customers are based on a negotiated price per test or on the basis of an…View ↗
The Company performs pharma research and development services for its biopharmaceutical customers utilizing its molecular information…View ↗
$152.9M
10-K for FY2017, filed Mar 7, 2018
$152.9M ↗
Physicians order clinical tests for patients; biopharmaceutical companies buy testing and research services. Certain hospitals, cancer centers, and other institutions have direct-bill relationships for tests.
10-K for FY2017, filed Mar 7, 2018We are a molecular information company focused on fundamentally changing the way in which patients with cancer are evaluated and treated.…View ↗
We derive revenue from the provision of molecular information services provided to our ordering physicians and biopharmaceutical customers…View ↗
The Company’s accounts receivable consists primarily of amounts due from biopharmaceutical customers, and from certain hospitals, cancer…View ↗
10-K for FY2017, filed Mar 7, 2018
Two customer arrangements, consisting of $50,286,000 and $15,450,000 of revenue, was greater than 10% of total revenue, representing 33%…View ↗
No. It lost $161.5M in FY2017.
10-K for FY2017, filed Mar 7, 2018
10-Q for Q2 FY2018, filed Aug 9, 2018
−$33.4MView ↗
8-K, filed Jul 31, 2018
As described in the Introductory Note above, on July 31, 2018, Merger Sub irrevocably accepted for payment all Shares validly tendered and…View ↗
8-K, filed Jun 19, 2018
On June 18, 2018, Foundation Medicine, Inc., a Delaware corporation (the “Company” or “Foundation Medicine”), entered into an Agreement and…View ↗
8-K, filed May 2, 2018
The company expects 2018 revenue will be in the range of $200 million to $220 million.View ↗
Grew. Revenue grew 5.3x in 4 years, from $29M in FY2013 to $152.9M in FY2017, about 52% a year.
Broader test lineup
The earlier report described FoundationOne and FoundationOne Heme; the latest also lists a blood-based assay and companion diagnostic tests, including an assay approved by the U.S. Food and Drug Administration for solid tumors.
10-K for FY2014, filed Mar 13, 2015Our first clinical products, FoundationOne® for solid tumors, and FoundationOne Heme for blood-based cancers, or hematologic malignancies…View ↗
Competes with Bio-Reference Laboratories, Laboratory Corporation of America Holdings, Quest Diagnostics, Caris Life Sciences, Guardant Health, Paradigm, NeoGenomics Laboratories, Abbott Laboratories, Qiagen, Roche Diagnostics, Thermo Fisher Scientific, Genomic Health, Myriad Genetics, Biocept, Exosome Diagnostics, Invitae, Personal Genome Diagnostics, MD Anderson Cancer Center, MSKCC, and University of Michigan
10-K for FY2017, filed Mar 7, 2018We may face competition from companies that offer products or have conducted research to profile genes and gene expression in various…View ↗
Loading...
